-
11.发明申请公开(公告)号：US20200123160A1
公开(公告)日：2020-04-23
申请号：US16538917
申请日：2019-08-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07B59/00 , A61K51/04 , A61K31/55 , A61K31/5386 , A61K31/435 , A61K31/553 , A61K31/541 , A61K31/5377 , A61K31/5025 , A61K31/497 , A61K31/496 , A61K31/454 , A61K31/4439 , A61K31/433 , C07D513/04 , C07D519/00 , A61K45/06
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US20150210684A1
公开(公告)日：2015-07-30
申请号：US14419559
申请日：2013-08-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tao Wang , Zhongxing Zhang , John F. Kadow , Nicholas A. Meanwell , Edward H. Ruediger , Clint A. James , Daniel H. Deon , David J. Carini , Barry L. Johnson
IPC: C07D471/04 , A61K45/06 , A61K31/4545 , C07D401/06 , A61K31/454
CPC classification number: C07D471/04 , A61K31/454 , A61K31/4545 , A61K45/06 , C07D401/06
Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formule (I): wherein A is selected from the group consisting of: formule (II) and wherein Z is selected from the group consisting of: formule (III): and. are useful as HIV attachment inhibitors.
Abstract translation: 式I化合物，包括其药学上可接受的盐：式（I）：其中A选自：结构（II），并且其中Z选自：基团（III）：和。 可用作HIV附着抑制剂。
-
公开(公告)号：US08642025B2
公开(公告)日：2014-02-04
申请号：US13650374
申请日：2012-10-12
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: A61K31/454 , A61K31/713 , A61K31/4178 , A61K31/5377 , A61K31/496 , A61K31/7056 , A61K38/05 , A61K38/21 , A61K38/20 , A61P31/14 , C07D413/14 , C07D401/14 , C07D403/14
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 还公开了含有这些化合物的药物组合物和使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20140018389A1
公开(公告)日：2014-01-16
申请号：US14027531
申请日：2013-09-16
Applicant: Bristol-Myers Squibb Company
Inventor： Rico Lavoie , John A. Bender , Jeffrey Lee Romine , Edward H. Ruediger , Carol Bachand , Omar D. Lopez , Qi Chen , Makonen Belema , John F. Kadow , Lawrence G. Hamann
IPC: C07D417/14 , C07D405/14 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/14
CPC classification number: C07D417/14 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/10 , C07D419/10 , C07D493/08
Abstract: This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
Abstract translation: 本公开涉及式（I）的新化合物或说明书中定义的和包含这些新化合物的组合物。 这些化合物是有用的抗病毒剂，特别是抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白的功能。 因此，本公开还涉及通过使用这些新化合物或包含这些新化合物的组合物治疗HCV相关疾病或病症的方法。
-
公开(公告)号：US20130280211A1
公开(公告)日：2013-10-24
申请号：US13919027
申请日：2013-06-17
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. ST. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: C07D403/14 , C07D401/14 , A61K45/06 , A61K31/5377 , C07F7/10 , A61K31/695 , A61K31/4178 , A61K31/4545
CPC classification number: C07D403/14 , A61K31/4178 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07F7/10
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
Patent Agency Ranking
公开(公告)号：US12037324B2
公开(公告)日：2024-07-16
申请号：US17861809
申请日：2022-07-11
Applicant: Université de Montréal , Bristol-Myers Squibb Company
Inventor： Eldon Scott Priestley , Samuel Kaye Reznik , Edward H. Ruediger , James R. Gillard , Oz Scott Halpern , Wen Jiang , Jeremy Richter , Rejean Ruel , Sasmita Tripathy , Wu Yang , Xiaojun Zhang
IPC: C07D401/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P9/04 , C07D233/90 , C07D235/26 , C07D239/20 , C07D257/04 , C07D271/07 , C07D401/10 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/10
CPC classification number: C07D401/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P9/04 , C07D233/90 , C07D235/26 , C07D239/20 , C07D257/04 , C07D271/07 , C07D401/10 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/10
Abstract: The present invention provides compounds of Formula (I):
wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.-
17.发明公开公开(公告)号：US20230242535A1
公开(公告)日：2023-08-03
申请号：US17902618
申请日：2022-09-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K31/454 , A61K31/5386 , A61K31/496 , A61K45/06 , C07B59/00 , A61K31/4439 , A61K31/5025 , A61K31/497 , A61K31/435 , A61K51/04 , A61K31/55 , C07D519/00 , A61K31/553 , A61K31/5377 , A61K31/433 , C07D513/04 , A61K31/541
CPC classification number: C07D487/04 , A61K31/55 , A61K31/433 , A61K31/435 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/541 , A61K31/553 , A61K31/4439 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K45/06 , A61K51/0453 , C07B59/002 , C07D513/04 , C07D519/00 , C07B2200/05
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US10822343B2
公开(公告)日：2020-11-03
申请号：US16538917
申请日：2019-08-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K45/06 , C07D519/00 , C07D513/04 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US09758487B2
公开(公告)日：2017-09-12
申请号：US15194980
申请日：2016-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Gan Wang , Lawrence G. Hamann
IPC: A61K38/20 , A61K31/4164 , A61K31/517 , A61K31/715 , A61K38/46 , A61P31/00 , C07D403/02 , C07D401/00 , C07D233/64 , C07D401/14 , C07D403/14 , A61K31/4178 , A61K45/06 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
20.发明申请公开(公告)号：US20170247395A1
公开(公告)日：2017-08-31
申请号：US15593534
申请日：2017-05-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jaques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestly , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07B59/00 , A61K31/433 , A61K31/5377 , A61K31/454 , A61K31/496 , A61K31/4439 , A61K31/497 , A61K31/541 , A61K31/553 , A61K31/5386 , C07D519/00 , A61K31/435 , C07D487/04 , A61K31/5025 , A61K31/55 , A61K51/04
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.04 seconds)
